CL2016001911A1 - Compuesto heterocíclico fusionado - Google Patents
Compuesto heterocíclico fusionadoInfo
- Publication number
- CL2016001911A1 CL2016001911A1 CL2016001911A CL2016001911A CL2016001911A1 CL 2016001911 A1 CL2016001911 A1 CL 2016001911A1 CL 2016001911 A CL2016001911 A CL 2016001911A CL 2016001911 A CL2016001911 A CL 2016001911A CL 2016001911 A1 CL2016001911 A1 CL 2016001911A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compound
- fused heterocyclic
- enteropeptidasa
- profilaxis
- benzofuran
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
COMPUESTOS DERIVADOS DE BENZOFURANO, COMO INHIBIDORES DE LA ENTEROPEPTIDASA; MEDICAMENTO QUE LOS COMPRENDE; Y SU USO PARA LA PROFILAXIS O EL TRATAMIENTO DE LA OBESIDAD Y DIABETES MELLITUS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014025832 | 2014-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001911A1 true CL2016001911A1 (es) | 2017-02-10 |
Family
ID=52589729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001911A CL2016001911A1 (es) | 2014-02-13 | 2016-07-28 | Compuesto heterocíclico fusionado |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9346776B2 (es) |
| EP (1) | EP3105213B1 (es) |
| JP (2) | JP6383427B2 (es) |
| KR (1) | KR102378454B1 (es) |
| CN (1) | CN105980370B (es) |
| AR (1) | AR099400A1 (es) |
| AU (1) | AU2015216438B2 (es) |
| BR (1) | BR112016018455B1 (es) |
| CA (1) | CA2938191C (es) |
| CL (1) | CL2016001911A1 (es) |
| CR (1) | CR20160367A (es) |
| CY (1) | CY1121534T1 (es) |
| DK (1) | DK3105213T3 (es) |
| DO (1) | DOP2016000206A (es) |
| EA (1) | EA032201B1 (es) |
| EC (1) | ECSP16067137A (es) |
| ES (1) | ES2717113T3 (es) |
| HR (1) | HRP20190369T1 (es) |
| HU (1) | HUE042709T2 (es) |
| IL (1) | IL246838B (es) |
| JO (1) | JO3472B1 (es) |
| LT (1) | LT3105213T (es) |
| MA (1) | MA39246A1 (es) |
| ME (1) | ME03422B (es) |
| MX (1) | MX368392B (es) |
| MY (1) | MY173607A (es) |
| NZ (1) | NZ722035A (es) |
| PE (1) | PE20161243A1 (es) |
| PH (1) | PH12016501582B1 (es) |
| PL (1) | PL3105213T3 (es) |
| PT (1) | PT3105213T (es) |
| RS (1) | RS58498B1 (es) |
| SG (1) | SG11201605654QA (es) |
| SI (1) | SI3105213T1 (es) |
| SM (1) | SMT201900175T1 (es) |
| TR (1) | TR201903892T4 (es) |
| TW (1) | TWI669297B (es) |
| UA (1) | UA118280C2 (es) |
| UY (1) | UY35994A (es) |
| WO (1) | WO2015122187A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507411TA (en) | 2013-03-13 | 2015-10-29 | Astellas Pharma Inc | Guanidinobenzoic acid ester compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
| JP6634070B2 (ja) * | 2015-03-27 | 2020-01-22 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| MX373154B (es) | 2015-04-03 | 2020-04-22 | Incyte Holdings Corp | Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1). |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| EP3705471A4 (en) | 2017-11-02 | 2021-08-11 | UBE Industries, Ltd. | TWO-HEAD PROTEASE INHIBITOR |
| AU2019265268C1 (en) | 2018-05-09 | 2022-08-04 | Lg Chem, Ltd. | Novel compound exhibiting enteropeptidase inhibitory activity |
| WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US20220281866A1 (en) | 2019-07-19 | 2022-09-08 | Janssen Pharmaceutica Nv | 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| WO2021166899A1 (ja) * | 2020-02-17 | 2021-08-26 | 宇部興産株式会社 | インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤 |
| CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
| CN111803652B (zh) * | 2020-08-04 | 2021-09-14 | 南通康是美生物科技有限公司 | 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2025115997A1 (ja) * | 2023-12-01 | 2025-06-05 | Ｅａファーマ株式会社 | 医薬組成物 |
| WO2025115989A1 (ja) * | 2023-12-01 | 2025-06-05 | Ｅａファーマ株式会社 | 医薬組成物 |
| WO2025211248A1 (ja) * | 2024-04-04 | 2025-10-09 | Ｅａファーマ株式会社 | 医薬組成物 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
| JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
| AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
| US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
| JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
| JPH06192085A (ja) | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
| EP0673924A4 (en) | 1992-12-10 | 1996-04-24 | Teikoku Chem Ind Co Ltd | PROPRIONIC ACID DERIVATIVE. |
| JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
| JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
| AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| JPH09124571A (ja) | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
| EP0893437A4 (en) | 1996-04-10 | 2000-12-27 | Ono Pharmaceutical Co | GUANIDINO TRYPTASE INHIBITOR |
| JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターｄ阻害剤 |
| JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体 |
| JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| AU2001269531A1 (en) | 2000-07-17 | 2002-01-30 | Takeda Chemical Industries Ltd. | Sulfone derivatives, process for their production and use thereof |
| MXPA05004505A (es) | 2002-11-01 | 2005-07-26 | Takeda Pharmaceutical | Agente para prevenir o tratar la neuropatia. |
| CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| WO2005030740A1 (ja) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | チアゾリン誘導体およびその用途 |
| JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US7671057B2 (en) | 2004-11-08 | 2010-03-02 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for type II diabetes comprising protease-inhibiting compound |
| WO2006050999A2 (en) | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Methods of reducing body fat |
| DE602004015169D1 (de) | 2004-11-26 | 2008-08-28 | Nutricia Nv | Kleinkindernahrung mit proteasehemmer |
| EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| JP2006348023A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミン誘導体を有効成分として含む血管新生阻害剤 |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | COMPOUND OF PHENOXYALKANOIC ACID |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| WO2007087130A2 (en) * | 2006-01-12 | 2007-08-02 | Merck & Co., Inc. | Hydroxyalkylarylamide derivatives |
| EP2431367A3 (en) | 2006-06-27 | 2012-07-04 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
| BRPI0807014A2 (pt) | 2007-02-09 | 2014-04-22 | Takeda Pharmaceutical | Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto. |
| EP2149550A4 (en) | 2007-04-27 | 2010-08-11 | Takeda Pharmaceutical | NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| EP2225261B1 (en) | 2007-12-03 | 2016-03-09 | Obe Therapy Biotechnology | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
| PL2511271T3 (pl) | 2009-12-07 | 2015-06-30 | Ea Pharma Co Ltd | Pochodna estru kwasu heteroarylokarboksylowego |
| ES2618024T3 (es) | 2011-06-07 | 2017-06-20 | Ea Pharma Co., Ltd. | Derivado de éster de ácido carboxílico heterocíclico |
| JP6048409B2 (ja) | 2011-09-15 | 2016-12-21 | アステラス製薬株式会社 | グアニジノ安息香酸化合物 |
| JP6174601B2 (ja) | 2012-01-03 | 2017-08-02 | オラムド エルティーディー． | 糖尿病を処置するための方法及び組成物 |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| US20150335715A1 (en) | 2013-01-03 | 2015-11-26 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| KR20150124985A (ko) | 2013-03-08 | 2015-11-06 | 암젠 인크 | 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법 |
| SG11201507411TA (en) | 2013-03-13 | 2015-10-29 | Astellas Pharma Inc | Guanidinobenzoic acid ester compound |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2015
- 2015-02-11 US US14/619,489 patent/US9346776B2/en active Active
- 2015-02-12 WO PCT/JP2015/000639 patent/WO2015122187A1/en not_active Ceased
- 2015-02-12 ES ES15706546T patent/ES2717113T3/es active Active
- 2015-02-12 AR ARP150100411A patent/AR099400A1/es active IP Right Grant
- 2015-02-12 NZ NZ722035A patent/NZ722035A/en unknown
- 2015-02-12 ME MEP-2019-89A patent/ME03422B/me unknown
- 2015-02-12 TR TR2019/03892T patent/TR201903892T4/tr unknown
- 2015-02-12 UY UY0001035994A patent/UY35994A/es not_active Application Discontinuation
- 2015-02-12 MY MYPI2016702925A patent/MY173607A/en unknown
- 2015-02-12 PL PL15706546T patent/PL3105213T3/pl unknown
- 2015-02-12 US US15/117,538 patent/US9969705B2/en active Active
- 2015-02-12 CN CN201580007800.9A patent/CN105980370B/zh active Active
- 2015-02-12 SI SI201530626T patent/SI3105213T1/sl unknown
- 2015-02-12 PE PE2016001239A patent/PE20161243A1/es unknown
- 2015-02-12 DK DK15706546.7T patent/DK3105213T3/en active
- 2015-02-12 CR CR20160367A patent/CR20160367A/es unknown
- 2015-02-12 AU AU2015216438A patent/AU2015216438B2/en active Active
- 2015-02-12 EA EA201691619A patent/EA032201B1/ru not_active IP Right Cessation
- 2015-02-12 JP JP2016550664A patent/JP6383427B2/ja active Active
- 2015-02-12 TW TW104104693A patent/TWI669297B/zh active
- 2015-02-12 RS RS20190324A patent/RS58498B1/sr unknown
- 2015-02-12 SG SG11201605654QA patent/SG11201605654QA/en unknown
- 2015-02-12 HR HRP20190369TT patent/HRP20190369T1/hr unknown
- 2015-02-12 HU HUE15706546A patent/HUE042709T2/hu unknown
- 2015-02-12 KR KR1020167025277A patent/KR102378454B1/ko active Active
- 2015-02-12 EP EP15706546.7A patent/EP3105213B1/en active Active
- 2015-02-12 PT PT15706546T patent/PT3105213T/pt unknown
- 2015-02-12 CA CA2938191A patent/CA2938191C/en active Active
- 2015-02-12 SM SM20190175T patent/SMT201900175T1/it unknown
- 2015-02-12 BR BR112016018455-6A patent/BR112016018455B1/pt active IP Right Grant
- 2015-02-12 MX MX2016010559A patent/MX368392B/es active IP Right Grant
- 2015-02-12 JO JOP/2015/0028A patent/JO3472B1/ar active
- 2015-02-12 MA MA39246A patent/MA39246A1/fr unknown
- 2015-02-12 LT LTEP15706546.7T patent/LT3105213T/lt unknown
- 2015-12-02 UA UAA201609351A patent/UA118280C2/uk unknown
-
2016
- 2016-07-19 IL IL246838A patent/IL246838B/en active IP Right Grant
- 2016-07-28 CL CL2016001911A patent/CL2016001911A1/es unknown
- 2016-08-10 PH PH12016501582A patent/PH12016501582B1/en unknown
- 2016-08-11 EC ECIEPI201667137A patent/ECSP16067137A/es unknown
- 2016-08-11 DO DO2016000206A patent/DOP2016000206A/es unknown
-
2018
- 2018-08-03 JP JP2018146459A patent/JP6529649B2/ja active Active
-
2019
- 2019-03-27 CY CY20191100356T patent/CY1121534T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CL2016001889A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1. | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| EA201891211A1 (ru) | Ингибиторы cxcr2 | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
| MX393838B (es) | Uso de compuestos heterociclicos para controlar nematodos. | |
| CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2017000505A1 (es) | Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016). | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| HUE037210T2 (hu) | Triciklusos heterociklusos vegyületek, mint foszfoinozitid 3-kináz inhibitorok | |
| CL2016002809A1 (es) | Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión. | |
| CR20170005A (es) | Derivados de insoindolina | |
| CL2015003635A1 (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa. | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| DOP2016000312A (es) | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 | |
| UY36221A (es) | Derivados de isoindolinona | |
| DK3390407T3 (da) | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser |